Biogen Sued by Neuroscience Company Sage Days After Buyout Offer
Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...
Hosted on MSN1d
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...
FiercePharma4d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $10.53 Consensus Target Price from Analysts
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...
BioPharma Dive4d
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
Yahoo Finance1d
Sage Therapeutics, Inc. (SAGE)
CAMBRIDGE, Mass., January 10, 2025--Sage Therapeutics, Inc. (Nasdaq: SAGE) ("The Company"), today confirmed that Biogen Inc. (Nasdaq: BIIB) ("Biogen") has submitted ...
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
bovnews1d
SAGE Stock Fluctuations: The Real Story
RBC Capital Mkts has recently raised SAGE Therapeutics Inc (SAGE) stock to Sector Perform rating, as announced on November 21, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James ...
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...